LexDanaLexDanabeta
Inventor

Sung-Ju Moon

Inventor
New Providence, NJ, US

Overview

28→
Patents
2001–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 28 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides19%
A61KPreparations for medical, dental or toiletry purposes18%
Y02ATechnologies for adaptation to climate change17%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%
A61NElectrotherapy11%
C07DHeterocyclic compounds11%
B82YSpecific uses or applications of nanostructures3%
C08BPolysaccharides3%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds3%
PatentTitleYear
10,751,422Antibody drug conjugates (ADC) that bind to FLT3 proteins202010,561,738Immunoconjugates with an intracellularly-cleavable linkage202010,322,193Immunoconjugates with an intracellularly-cleavable linkage201910,265,414Immunoconjugates with an intracellularly-cleavable linkage201910,064,957Immunoconjugates with an intracellularly-cleavable linkage20189,974,865Antibody drug conjugates (ADC) that bind to FLT3 proteins20189,707,300'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'20179,700,634'Immunoconjugates with an intracellularly-cleavable linkage'20179,675,706'Immunoconjugates with an intracellularly-cleavable linkage'20179,480,756'Immunoconjugates with an intracellularly-cleavable linkage'20169,345,783'Immunoconjugates with an intracellularly-cleavable linkage'20169,233,172'Immunoconjugates with an intracellularly-cleavable linkage'20169,198,978'Immunoconjugates with an intracellularly-cleavable linkage'20159,138,485'Immunoconjugates with an intracellularly-cleavable linkage'20159,102,735'Immunoconjugates with an intracellularly-cleavable linkage'20158,999,344'Immunoconjugates with an intracellularly-cleavable linkage'20158,889,835'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'20148,834,886'Camptothecin-binding moiety conjugates'20148,759,496'Immunoconjugates with an intracellularly-cleavable linkage'20148,741,300'Immunoconjugates with an intracellularly-cleavable linkage'20148,617,558'Camptothecin-binding moiety conjugates'20138,338,140'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'20128,268,317'Camptothecin-binding moiety conjugates'20128,080,250'Immunoconjugates with an intracellularly-cleavable linkage'20118,067,006'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'20117,999,083'Immunoconjugates with an intracellularly-cleavable linkage'20117,591,994'Camptothecin-binding moiety conjugates'20096,258,942'TADG7: a novel gene expressed in ovarian tumor and uses thereof'2001

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2001Based in Seoul, KR· patent location history
2009–2020Patents assigned to IMMUNOMEDICS INC (25)· patent assignee history
2009Based in Denville, NJ, US· patent location history
2011–2014Patents assigned to GOLDENBERG DAVID M (6)· patent assignee history
2011–2014Patents assigned to GOVINDAN SERENGULAM V (6)· patent assignee history
2011–2014Patents assigned to MOON SUNG-JU (6)· patent assignee history
2011–2020Based in New Providence, NJ, US· patent location history
2018–2020Patents assigned to AGENSYS INC (2)· patent assignee history
2018–2020Based in Santa Monica, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
IMMUNOMEDICS INC252009–2020
GOLDENBERG DAVID M62011–2014
GOVINDAN SERENGULAM V62011–2014
MOON SUNG-JUself62011–2014
AGENSYS INC22018–2020
Locations
LocationPatentsSpan
New Providence, New Jersey, US242011–2020
Santa Monica, California, US22018–2020
Denville, New Jersey, US12009
Seoul, KR12001